HC Wainwright reiterates Buy on Alnylam, lifts $455 target
HC Wainwright & Co. reiterated a Buy rating on Alnylam Pharmaceuticals and set a $455.00 price target, implying 89.9% upside from the Sep 18 close of $239.56.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.